Alliance for Test to Detect Early Kidney Disease
By HospiMedica staff writers
Posted on 10 Sep 2002
The signing of a multiyear agreement to develop a diagnostic test for the early detection of kidney disease has been announced by AusAm Biotechnologies, Inc. (Santa Monica, CA, USA) and Esoterix, Inc. (also in Santa Monica).Posted on 10 Sep 2002
Upon obtaining clearance from the US Food and Drug Administration (FDA), AusAm Biotechnologies, Inc. will provide Esoterix with a quantitative urinary albumin test for detection of early kidney disease. AusAm is engaged in the development of urine-based diagnostic tests for a wide variety of diseases. Recent research has uncovered a form of intact albumin that may provide an early indication of kidney disease. The company says its test may allow doctors to diagnose the onset of kidney disease earlier and with greater accuracy than is currently possible. Microalbuminuria testing has emerged as one way to lower medical costs while improving patient outcomes.
"The agreement with AusAm furthers our initiatives to expand Esoterix's involvement in developing for the market highly specific assays in endocrinology,” said Dr. Greg Stelzer, chief scientific officer of Esoterix, Inc.
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Immunofluorescence Analyzer
IFA System
Rapid Sepsis Test
SeptiCyte RAPID
